Study reveals risk predictors for short bowel syndrome in Crohn’s disease | All the latest medical news on the portal. :- Medznat
EN | RU
EN | RU

Help Support

By clicking the "Submit" button, you accept the terms of the User Agreement, including those related to the processing of your personal data. More about data processing in the Policy.
Back

Study reveals risk predictors for short bowel syndrome in Crohn’s disease

Study reveals risk predictors for short bowel syndrome in Crohn’s disease Study reveals risk predictors for short bowel syndrome in Crohn’s disease
Study reveals risk predictors for short bowel syndrome in Crohn’s disease Study reveals risk predictors for short bowel syndrome in Crohn’s disease

What's new?

Clinicians should pay attention to predictors that may increase the risk for short bowel syndrome in Crohn’s disease patients.

A recent study revealed three vital predictors influencing the occurrence of short bowel syndrome in patients suffering from Crohn's disease: (a) Montreal B1 behavior at diagnosis, (b) intravenous steroids use, and (c) budesonide use.

A retrospective case-control single-center study was conducted to explore independent predictors for short bowel syndrome in Crohn's disease patients to allow the development of best therapeutic management and lower surgery rate.

The study recruited adult patients (older than 18 years) visiting the hospital for Crohn's disease or short bowel syndrome between 2012 and 2019. Overall, 410 Crohn's disease patients were included (369 without short bowel syndrome, 41 with short bowel syndrome). Each Crohn's disease patient with short bowel syndrome was matched to nine controls.

Subjects suffering from short bowel syndrome reported a remarkably higher number of bowel resections compared to the control group. The median time before the first surgery was not different compared to the control group, as shown in the table below:

A raised requirement for parenteral support was witnessed in patients with end-jejunostomy short bowel syndrome compared to patients with jejunocolic and jejunoileal short bowel syndrome (70.6% vs 25% and 0%). Montreal B1 behavior and budesonide treated-patients were at minimized risk of short bowel syndrome, while intravenous steroid treated-patients were at an elevated risk.

Thus, to prevent the onset of short bowel syndrome in Crohn’s disease patients, evaluation of the risk predictors should be done in daily clinical practice. Further studies should focus on assessing whether treatment with biologics can be a viable alternative to steroids to minimize the risk of short bowel syndrome. 

Source:

Digestive and Liver Disease

Article:

Predictors for short bowel syndrome in Crohn’s disease

Authors:

Simon Vaillant et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies ru en ua
Try: